Stocktoria
REGENXBIO Inc. RGNX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-09-17
REGENXBIO Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% |
| Net margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% |
| FCF margin | -74.1% | -210.7% | -253.1% | -211.3% | 28.6% |
| Return on assets | -42.8% | -48.7% | -45.9% | -33.6% | 11.5% |
| Return on equity | -188.7% | -87.5% | -84.5% | -54.3% | 16.7% |
| Current ratio | 2.38 | 2.69 | 2.57 | 3.19 | 3.98 |
| Revenue growth | 104.5% | -7.7% | -19.9% | -76.0% | 204.3% |
Source: SEC EDGAR filings · CIK 0001590877 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.